Is Calidi Biotherapeutics Stock a Good Investment?
Calidi Biotherapeutics Investment Advice | CLDI |
- Examine Calidi Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Calidi Biotherapeutics' leadership team and their track record. Good management can help Calidi Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Calidi Biotherapeutics' business and its evolving consumer preferences.
- Compare Calidi Biotherapeutics' performance and market position to its competitors. Analyze how Calidi Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Calidi Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Calidi Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Calidi Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Calidi Biotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Calidi Biotherapeutics Stock
Researching Calidi Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company shares are held by institutions such as insurance companies. The book value of Calidi Biotherapeutics was currently reported as 0.21. The company recorded a loss per share of 1.12. Calidi Biotherapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 15th of July 2024.
To determine if Calidi Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Calidi Biotherapeutics' research are outlined below:
| Calidi Biotherapeutics is way too risky over 90 days horizon | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Calidi Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Latest headline from gurufocus.com: Join Calidi Biotherapeutics Exclusive Live Investor Webinar and QA Session on July 24 ... |
Calidi Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
Calidi Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Calidi Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Calidi Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Calidi Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Calidi Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.17 | -0.14 | 0.03 | 17 | ||
2025-05-14 | 2025-03-31 | -0.25 | -0.18 | 0.07 | 28 | ||
2024-05-14 | 2024-03-31 | -0.28 | -0.2 | 0.08 | 28 | ||
2025-03-31 | 2024-12-31 | -0.09 | -0.27 | -0.18 | 200 | ||
2024-03-15 | 2023-12-31 | -0.2 | -0.48 | -0.28 | 140 | ||
2024-11-13 | 2024-09-30 | -0.19 | -0.65 | -0.46 | 242 | ||
2024-08-14 | 2024-06-30 | -0.19 | -1.4 | -1.21 | 636 |
Calidi Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.03 M.Market Cap |
|
Calidi Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.64) | |
| Return On Capital Employed | (4.65) | (4.41) | |
| Return On Assets | (1.56) | (1.64) | |
| Return On Equity | (14.43) | (13.71) |
Determining Calidi Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Calidi Biotherapeutics is a good buy. For example, gross profit margin measures Calidi Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Calidi Biotherapeutics' profitability and make more informed investment decisions.
Evaluate Calidi Biotherapeutics' management efficiency
Calidi Biotherapeutics has return on total asset (ROA) of (1.1174) % which means that it has lost $1.1174 on every $100 spent on assets. This is way below average. Calidi Biotherapeutics' management efficiency ratios could be used to measure how well Calidi Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.64. The Calidi Biotherapeutics' current Return On Capital Employed is estimated to increase to -4.41. As of now, Calidi Biotherapeutics' Non Currrent Assets Other are increasing as compared to previous years. The Calidi Biotherapeutics' current Total Current Assets is estimated to increase to about 10.7 M, while Total Assets are projected to decrease to under 13.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.25 | 0.23 | |
| Tangible Book Value Per Share | 0.25 | 0.23 | |
| Enterprise Value Over EBITDA | (0.31) | (0.32) | |
| Price Book Value Ratio | 6.00 | 6.30 | |
| Enterprise Value Multiple | (0.31) | (0.32) | |
| Price Fair Value | 6.00 | 6.30 | |
| Enterprise Value | 3.2 B | 2.8 B |
Management at Calidi Biotherapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.937 |
Basic technical analysis of Calidi Stock
As of the 23rd of July, Calidi Biotherapeutics shows the Downside Deviation of 8.09, risk adjusted performance of 0.0954, and Mean Deviation of 7.92. Calidi Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Calidi Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Calidi Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Calidi Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Calidi Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Calidi Biotherapeutics' Outstanding Corporate Bonds
Calidi Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Calidi Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Calidi bonds can be classified according to their maturity, which is the date when Calidi Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Calidi Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Calidi Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0954 | |||
| Market Risk Adjusted Performance | 0.8618 | |||
| Mean Deviation | 7.92 | |||
| Semi Deviation | 6.6 | |||
| Downside Deviation | 8.09 | |||
| Coefficient Of Variation | 1050.4 | |||
| Standard Deviation | 16.45 | |||
| Variance | 270.76 | |||
| Information Ratio | 0.0844 | |||
| Jensen Alpha | 1.25 | |||
| Total Risk Alpha | (1.51) | |||
| Sortino Ratio | 0.1715 | |||
| Treynor Ratio | 0.8518 | |||
| Maximum Drawdown | 129.88 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 20.34 | |||
| Downside Variance | 65.48 | |||
| Semi Variance | 43.51 | |||
| Expected Short fall | (14.64) | |||
| Skewness | 4.39 | |||
| Kurtosis | 25.63 |
| Risk Adjusted Performance | 0.0954 | |||
| Market Risk Adjusted Performance | 0.8618 | |||
| Mean Deviation | 7.92 | |||
| Semi Deviation | 6.6 | |||
| Downside Deviation | 8.09 | |||
| Coefficient Of Variation | 1050.4 | |||
| Standard Deviation | 16.45 | |||
| Variance | 270.76 | |||
| Information Ratio | 0.0844 | |||
| Jensen Alpha | 1.25 | |||
| Total Risk Alpha | (1.51) | |||
| Sortino Ratio | 0.1715 | |||
| Treynor Ratio | 0.8518 | |||
| Maximum Drawdown | 129.88 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 20.34 | |||
| Downside Variance | 65.48 | |||
| Semi Variance | 43.51 | |||
| Expected Short fall | (14.64) | |||
| Skewness | 4.39 | |||
| Kurtosis | 25.63 |
Consider Calidi Biotherapeutics' intraday indicators
Calidi Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Calidi Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Calidi Biotherapeutics time-series forecasting models is one of many Calidi Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Calidi Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Calidi Stock media impact
There is far too much social signal, news, headlines, and media speculation about Calidi Biotherapeutics that are available to investors today. This information is accessible both publicly - through Calidi Biotherapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Calidi-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Calidi Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Calidi Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Calidi Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Calidi Biotherapeutics alpha.
Calidi Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Calidi Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Calidi Biotherapeutics Corporate Management
| Andrew Jackson | Chief Officer | Profile | |
| PharmD Santidrian | Head Officer | Profile | |
| Stephen Thesing | Chief Officer | Profile | |
| Thomas Herrmann | Managing Development | Profile | |
| Wendy Esq | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calidi Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Calidi Biotherapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.